Evaluation of Intra-Lesional Interleukin 2 for the Treatment of In-Transit Melanoma Disease: L'évaluation De L'interleukine-2 Intralésionnelle Pour Traiter Les Mélanomes En Transit

Overview

Journal Plast Surg (Oakv)

Specialty General Surgery

Date 2021 Feb 22

PMID 33614534

Authors

Beatriz Lopez-Obregon

Marcio P Barreto

Allison Fyfe

Greg McKinnon

Carmen Webb

Claire Temple-Oberle

Affiliations

Soon will be listed here.

Abstract

Background: Intra-lesional interleukin 2 (IL-2) therapy trials for the treatment of in-transit melanoma using different treatment protocols have been published reporting varied results. This study assesses the results of IL-2 therapy in our institution and to evaluate the reproducibility of our response rates when using the same treatment protocol as another Canadian centre.

Methods: A retrospective review was undertaken of patients with in-transit melanoma who were treated with intralesional IL-2 in a single institution from 2010 to 2016. Responses were evaluated using RECIST criteria. Demographic data, tumour characteristics, follow-up data, in-transit-free interval, and survival data were collected and analysed.

Results: Forty-nine patients were identified. Overall tumour response rate was 72%, including complete response in 23 patients (47%) and partial response in 12 patients (24%). Stable disease was observed in 4% of patients and progressive disease in 25%. The main side effects were minor discomfort with injections and auto-limited flu-like symptoms. The presence of tumour-infiltrating lymphocytes may be a predictor of better response.

Conclusion: This study confirms prior experience with intra-lesional IL-2, demonstrating it to be an effective, safe, and well-tolerated therapy for in-transit melanoma. Tumour-infiltrating lymphocytes as a predictor of better response warrant further study.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Clark Jr W, Elder D, Guerry 4th D, Braitman L, Trock B, Schultz D . Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81(24):1893-904. DOI: 10.1093/jnci/81.24.1893. View

Lee N, Zakka L, Mihm Jr M, Schatton T . Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016; 48(2):177-87. DOI: 10.1016/j.pathol.2015.12.006. View

Kotoula V, Chatzopoulos K, Lakis S, Alexopoulou Z, Timotheadou E, Zagouri F . Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget. 2015; 7(4):5074-87. PMC: 4826267. DOI: 10.18632/oncotarget.6231. View

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F . Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013; 31(7):860-7. DOI: 10.1200/JCO.2011.41.0902. View

Ellebaek E, Iversen T, Junker N, Donia M, Engell-Noerregaard L, Met O . Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med. 2012; 10:169. PMC: 3514199. DOI: 10.1186/1479-5876-10-169. View

Hassan S, Petrella T, Zhang T, Kamel-Reid S, Nordio F, Baccarelli A . Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease. Ann Surg Oncol. 2014; 22(6):1950-8. DOI: 10.1245/s10434-014-4199-z. View

Radny P, Caroli U, Bauer J, Paul T, Schlegel C, Eigentler T . Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer. 2003; 89(9):1620-6. PMC: 2394422. DOI: 10.1038/sj.bjc.6601320. View

Wolchok J, Hoos A, ODay S, Weber J, Hamid O, Lebbe C . Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23):7412-20. DOI: 10.1158/1078-0432.CCR-09-1624. View

10.

Boyd K, Wehrli B, Temple C . Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol. 2011; 104(7):711-7. DOI: 10.1002/jso.21968. View

11.

Diem S, Ali O, Ackermann C, Bomze D, Koelzer V, Jochum W . Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunol Immunother. 2017; 67(1):39-45. PMC: 11028172. DOI: 10.1007/s00262-017-2061-4. View

12.

Beasley G, Petersen R, Yoo J, McMahon N, Aloia T, Petros W . Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008; 15(8):2195-205. DOI: 10.1245/s10434-008-9988-9. View

13.

Byers B, Temple-Oberle C, Hurdle V, McKinnon J . Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review. J Surg Oncol. 2014; 110(6):770-5. DOI: 10.1002/jso.23702. View

14.

Takkenberg R, Vrouenraets B, van Geel A, Nieweg O, Noorda E, Eggermont A . Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol. 2005; 91(2):107-11. DOI: 10.1002/jso.20297. View

15.

Weide B, Derhovanessian E, Pflugfelder A, Eigentler T, Radny P, Zelba H . High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer. 2010; 116(17):4139-46. DOI: 10.1002/cncr.25156. View

16.

Ridolfi L, Ridolfi R . Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogastroenterology. 2002; 49(44):335-9. View

17.

Dehesa L, Vilar-Alejo J, Valeron-Almazan P, Carretero G . [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2]. Actas Dermosifiliogr. 2009; 100(7):571-85. View

18.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D . Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25(8):1544-50. DOI: 10.1093/annonc/mdu112. View

19.

Fraker D . Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr Treat Options Oncol. 2004; 5(3):173-84. DOI: 10.1007/s11864-004-0009-3. View

20.

Santoiemma P, Powell Jr D . Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 2015; 16(6):807-20. PMC: 4622931. DOI: 10.1080/15384047.2015.1040960. View